Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
The Journal of Targeted Therapies in Cancer
March 2012
Clinical Articles
Full PDF Version of OncologyLive Targeted Therapy News from March 2012
Colorectal Tumor Marker: Molecular Evaluation Sheds Light on Negative Lymph Node Status
Changing Paradigms for NSCLC in Personalized Therapy Era
Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab
Prostate Cancer Armamentarium Expanding
Emerging Biomarker Science Presents Practical Questions
PARP Inhibition Explored in Triple-Negative Breast Cancer
Clinicians Face Challenges Integrating New Therapeutics
Trial Shows Denosumab Delays Development of Bone Metastasis in Hormone-Resistant Prostate Cancer
New Assays Open Window in Evaluating Leukemia Types
Using Molecular Markers in AML for Prediction, Treatment, and Monitoring
Predictive Markers Needed for Adjuvant Chemotherapy
Hospitals for Vulnerable Patients Less Likely to Provide Optimal Lung Cancer Care
FDA Approves Axitinib for Advanced Kidney Cancer Patients
Two New Options Represent Breakthroughs
Hair Professionals Often Check Customers for Worrisome Skin Lesions
Better Communication of Complex Medical Information Needed
Some Follicular Lymphoma Patients May Benefit From Treatment Delay
The Hope and Challenges of Personalized Medicine
Targeted Therapies Trials in Progress
NICE’s Reluctance to Back Yervoy Turns on Cost-Benefit Perceptions
Pierre Hainaut, PhD: Awakening the “Guardian of the Genomeâ€
JTT Articles
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
Researchers Look to CAR T-Cell Therapy as Immunotherapy Outcomes Diminish in Glioblastoma
>> View Peer-Reviewed Articles
Most Popular
Pembrolizumab Approved by FDA for Stage III Melanoma
Encouraging Activity Seen With Pembrolizumab in Non-Clear Cell RCC
Not Always Imperative to Change Drug Class After Disease Progression, Myeloma Expert Says
Ibrutinib and Palbociclib Combination Active in Previously Treated MCL